SCHEMBL4355894

SCHEMBL4355894

Oc1c(F)cccc1NC(=S)NCCc1ccccc1

nearest known ligand 0.79

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 5/20 0.79
RAB9A P51151 5/20 0.79
CYP1A2 P05177 4/20 0.79
CYP2D6 P10635 4/20 0.79
CYP2C19 P33261 4/20 0.79
CYP2C9 P11712 3/20 0.79
CYP3A4 P08684 3/20 0.79
ALDH1A1 P00352 6/20 0.65
ALOX12 P18054 5/20 0.65
MEN1 O00255 4/20 0.65
KMT2A Q03164 4/20 0.65
HPGD P15428 2/20 0.65
POLB P06746 1/20 0.65
SMN1; SMN2 Q16637 4/20 0.64
LMNA P02545 4/20 0.64
HTT P42858 1/20 0.64
MAPT P10636 3/20 0.61
GAA P10253 2/20 0.58
MAOA P21397 1/20 0.57
MAOB P27338 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4341540 0.86 MEN1 (0.62) NPC1RAB9ACYP1A2CYP2D6CYP2C19
SCHEMBL4346353 0.85 ALDH1A1 (0.80) NPC1RAB9ACYP1A2CYP2D6CYP2C19
SCHEMBL4356054 0.83 MAPK1 (0.70) NPC1RAB9ACYP1A2CYP2D6CYP2C19
SCHEMBL4351245 0.83 TRPV1 (0.58) NPC1RAB9ACYP1A2CYP2D6CYP2C19
SCHEMBL4350090 0.82 SMN1; SMN2 (0.73) NPC1RAB9ACYP1A2CYP2D6CYP2C19
SCHEMBL27782813 0.79 SMN1; SMN2 (0.76) NPC1RAB9ACYP1A2CYP2D6CYP2C19
SCHEMBL4349029 0.79 RAB9A (0.68) NPC1RAB9ACYP1A2CYP2D6CYP2C19
SCHEMBL4350067 0.78 SMN1; SMN2 (0.70) NPC1RAB9ACYP1A2CYP2D6CYP2C19
SCHEMBL6958878 0.77 MAPT (0.83) NPC1RAB9ACYP1A2CYP2D6CYP2C19
SCHEMBL4347353 0.76 KMT2A (0.58) NPC1RAB9ACYP1A2CYP2D6CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110065760-A1 COMPOUNDS FOR THE INHIBITION OF ROTAMASES AND USE THEREOF JERINI AG (DE) 2011-03-17 US claimed
EP-2100876-A2 New compounds for the inhibition of rotamases and use thereof Jerini AG (DE) 2009-09-16 EP claimed
US-20070054904-A1 Phenol derivatives and their use as rotamase inhibitors JERINI AG (DE) 2007-03-08 US claimed
CN-1701061-A Novel compounds for inhibiting rotamase enzymes and uses thereof JERINI AG (DE) 2005-11-23 CN claimed
EP-2100876-A2 New compounds for the inhibition of rotamases and use thereof Jerini AG (DE) 2009-09-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110065760-A1 COMPOUNDS FOR THE INHIBITION OF ROTAMASES AND USE THEREOF NR1I3, NR1D1, NR1D2 NPC1 815/4885RAB9A 4228/4885CYP1A2 215/4885
US-20070054904-A1 Phenol derivatives and their use as rotamase inhibitors NR1I3, NR1D1, NR1D2 NPC1 1189/4885RAB9A 4588/4885CYP1A2 147/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.